Impaired Health‐Related Quality of Life in Patients With Hemophilia A With Inhibitors
Patients’ responses to surveys assessing quality of life indicated impairment in both adults and adolescents.
Hemophilia
Intracranial Bleeding Rates in Neonates With Hemophilia by Mode of Delivery
Neonates with hemophilia who were delivered either vaginally or by Cesarean section had similar rates of intracranial bleeding.
Management of Intracranial Hemorrhage in Patients With Hemophilia
Researchers reviewed 33 studies published over a span of 20 years to identify risk factors and symptoms of intracranial hemorrhage in patients with hemophilia.
Once-Weekly Prophylaxis for Low-Bleeding Patients With Severe Hemophilia A
Once-weekly prophylactic injection of glycopegylated recombinant factor VIII (N8‐GP) for severe hemophilia A appears to be efficacious and safe, according to results from the pathfinder 2 extension phase. The study, published in Haemophilia, included patients aged 12 years or older with severe hemophilia A who had experienced up to 2 bleeds during the pathfinder 2…
Safety of Buccal Administration of Dental Anesthetic in Patients With Hemophilia
Current guidelines do not adequately inform management of patients with inherited bleeding disorders undergoing routine dental procedures.
New Tool for Reconstituting Factor VIII for Hemophilia A Prophylaxis
Simplifying factor VIII reconstitution may increase treatment adherence and satisfaction in patients with hemophilia A.
Advances in the Treatment of Hemophilia: Clinical Gene Therapy
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
Esperoct Approval Provides New Treatment Option for Hemophilia A
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
Long-Term Outcome Profile in Patients With Acquired Hemophilia A
Underlying lymphoproliferative syndromes, male gender, and older age may be predictive of relapse in patients with acquired hemophilia A.
Episodic Treatment Compared With Prophylaxis in Patients With Hemophilia A
Researchers assessed safety outcomes in patients with hemophilia A without inhibitors.
Next post in Bleeding Disorders
